Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study

Citadel J. Cabasag; John Butler; Melina Arnold; Mark Rutherford; Aude Bardot; Jacques Ferlay; Eileen Morgan; Bjørn Møller; Anna Gavin; Charles H. Norell; Samantha Harrison; Nathalie Saint-Jacques; Michael Eden; Brian Rous; Andy Nordin; Louise Hanna; Janice Kwon; Paul A. Cohen; Alon D. Altman; Lorraine Shack; Serena Kozie; Gerda Engholm; Prithwish De; Peter Sykes; Geoff Porter; Sarah Ferguson; Paul Walsh; Richard Trevithick; Hanna Tervonen; Dianne O'Connell; Freddie Bray; Isabelle Soerjomataram

doi:10.1016/j.ygyno.2019.12.047

Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study

Citadel J. Cabasag^*, John Butler, Melina Arnold, Mark Rutherford, Aude Bardot, Jacques Ferlay, Eileen Morgan, Bjørn Møller, Anna Gavin, Charles H. Norell, Samantha Harrison, Nathalie Saint-Jacques, Michael Eden, Brian Rous, Andy Nordin, Louise Hanna, Janice Kwon, Paul A. Cohen, Alon D. Altman, Lorraine ShackSerena Kozie, Gerda Engholm, Prithwish De, Peter Sykes, Geoff Porter, Sarah Ferguson, Paul Walsh, Richard Trevithick, Hanna Tervonen, Dianne O'Connell, Freddie Bray, Isabelle Soerjomataram

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

Abstract

Objective: The study aims to evaluate the differences in ovarian cancer survival by age and stage at diagnosis within and across seven high-income countries. Methods: We analyzed data from 58,161 women diagnosed with ovarian cancer during 2010–2014, followed until 31 December 2015, from 21 population-based cancer registries in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Comparisons of 1-year and 3-year age- and stage-specific net survival (NS) between countries were performed using the period analysis approach. Results: Minor variation in the stage distribution was observed between countries, with most women being diagnosed with ‘distant’ stage (ranging between 64% in Canada and 71% in Norway). The 3-year all-ages NS ranged from 45 to 57% with Australia (56%) and Norway (57%) demonstrating the highest survival. The proportion of women with ‘distant’ stage was highest for those aged 65–74 and 75–99 years and varied markedly between countries (range:72–80% and 77–87%, respectively). The oldest age group had the lowest 3-year age-specific survival (20–34%), and women aged 65–74 exhibited the widest variation across countries (3-year NS range: 40–60%). Differences in survival between countries were particularly stark for the oldest age group with ‘distant’ stage (3-year NS range: 12% in Ireland to 24% in Norway). Conclusions: International variations in ovarian cancer survival by stage exist with the largest differences observed in the oldest age group with advanced disease. This finding endorses further research investigating international differences in access to and quality of treatment, and prevalence of comorbid conditions particularly in older women with advanced disease.

Original language	English
Pages (from-to)	234-244
Number of pages	11
Journal	Gynecologic Oncology
Volume	157
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2019.12.047
Publication status	Published - Apr 2020

Bibliographical note

Funding Information:
The ICBP is funded by the Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; NHS England; Norwegian Cancer Society; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry; DG Health and Social Care, Scottish Government; Western Australia Department of Health; Public Health Wales NHS Trust. The authors would also like to thank the ICBP management team of Cancer Research UK for managing the program, the ICBP SurvMark-2 Local Leads for advice to understand the data, for their contributions to the study protocol and interpretation of the results and the ICBP Clinical Committees for their advice. We are also grateful to the ICBP SurvMark-2 Academic Reference Group for providing independent peer review and advice for the study protocol and analysis plan development. Finally we are thankful to the ICBP Program Board for their oversight and direction. A complete list of all investigators can be found in page 2 of the Supplementary Materials. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.

Funding Information:
The ICBP is funded by the Canadian Partnership Against Cancer ; Cancer Council Victoria ; Cancer Institute New South Wales ; Cancer Research UK ; Danish Cancer Society ; National Cancer Registry Ireland ; The Cancer Society of New Zealand ; NHS England ; Norwegian Cancer Society ; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry ; DG Health and Social Care, Scottish Government ; Western Australia Department of Health ; Public Health Wales NHS Trust . The authors would also like to thank the ICBP management team of Cancer Research UK for managing the program, the ICBP SurvMark-2 Local Leads for advice to understand the data, for their contributions to the study protocol and interpretation of the results and the ICBP Clinical Committees for their advice. We are also grateful to the ICBP SurvMark-2 Academic Reference Group for providing independent peer review and advice for the study protocol and analysis plan development. Finally we are thankful to the ICBP Program Board for their oversight and direction. A complete list of all investigators can be found in page 2 of the Supplementary Materials.

Publisher Copyright:
© 2020 World Health Organization

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ygyno.2019.12.047

Cite this

Cabasag, C. J., Butler, J., Arnold, M., Rutherford, M., Bardot, A., Ferlay, J., Morgan, E., Møller, B., Gavin, A., Norell, C. H., Harrison, S., Saint-Jacques, N., Eden, M., Rous, B., Nordin, A., Hanna, L., Kwon, J., Cohen, P. A., Altman, A. D., ... Soerjomataram, I. (2020). Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study. Gynecologic Oncology, 157(1), 234-244. https://doi.org/10.1016/j.ygyno.2019.12.047

@article{3a0dd3bdcb1f4677893674306aef64c0,

title = "Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study",

abstract = "Objective: The study aims to evaluate the differences in ovarian cancer survival by age and stage at diagnosis within and across seven high-income countries. Methods: We analyzed data from 58,161 women diagnosed with ovarian cancer during 2010–2014, followed until 31 December 2015, from 21 population-based cancer registries in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Comparisons of 1-year and 3-year age- and stage-specific net survival (NS) between countries were performed using the period analysis approach. Results: Minor variation in the stage distribution was observed between countries, with most women being diagnosed with {\textquoteleft}distant{\textquoteright} stage (ranging between 64% in Canada and 71% in Norway). The 3-year all-ages NS ranged from 45 to 57% with Australia (56%) and Norway (57%) demonstrating the highest survival. The proportion of women with {\textquoteleft}distant{\textquoteright} stage was highest for those aged 65–74 and 75–99 years and varied markedly between countries (range:72–80% and 77–87%, respectively). The oldest age group had the lowest 3-year age-specific survival (20–34%), and women aged 65–74 exhibited the widest variation across countries (3-year NS range: 40–60%). Differences in survival between countries were particularly stark for the oldest age group with {\textquoteleft}distant{\textquoteright} stage (3-year NS range: 12% in Ireland to 24% in Norway). Conclusions: International variations in ovarian cancer survival by stage exist with the largest differences observed in the oldest age group with advanced disease. This finding endorses further research investigating international differences in access to and quality of treatment, and prevalence of comorbid conditions particularly in older women with advanced disease.",

author = "Cabasag, {Citadel J.} and John Butler and Melina Arnold and Mark Rutherford and Aude Bardot and Jacques Ferlay and Eileen Morgan and Bj{\o}rn M{\o}ller and Anna Gavin and Norell, {Charles H.} and Samantha Harrison and Nathalie Saint-Jacques and Michael Eden and Brian Rous and Andy Nordin and Louise Hanna and Janice Kwon and Cohen, {Paul A.} and Altman, {Alon D.} and Lorraine Shack and Serena Kozie and Gerda Engholm and Prithwish De and Peter Sykes and Geoff Porter and Sarah Ferguson and Paul Walsh and Richard Trevithick and Hanna Tervonen and Dianne O'Connell and Freddie Bray and Isabelle Soerjomataram",

note = "Funding Information: The ICBP is funded by the Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; NHS England; Norwegian Cancer Society; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry; DG Health and Social Care, Scottish Government; Western Australia Department of Health; Public Health Wales NHS Trust. The authors would also like to thank the ICBP management team of Cancer Research UK for managing the program, the ICBP SurvMark-2 Local Leads for advice to understand the data, for their contributions to the study protocol and interpretation of the results and the ICBP Clinical Committees for their advice. We are also grateful to the ICBP SurvMark-2 Academic Reference Group for providing independent peer review and advice for the study protocol and analysis plan development. Finally we are thankful to the ICBP Program Board for their oversight and direction. A complete list of all investigators can be found in page 2 of the Supplementary Materials. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. Funding Information: The ICBP is funded by the Canadian Partnership Against Cancer ; Cancer Council Victoria ; Cancer Institute New South Wales ; Cancer Research UK ; Danish Cancer Society ; National Cancer Registry Ireland ; The Cancer Society of New Zealand ; NHS England ; Norwegian Cancer Society ; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry ; DG Health and Social Care, Scottish Government ; Western Australia Department of Health ; Public Health Wales NHS Trust . The authors would also like to thank the ICBP management team of Cancer Research UK for managing the program, the ICBP SurvMark-2 Local Leads for advice to understand the data, for their contributions to the study protocol and interpretation of the results and the ICBP Clinical Committees for their advice. We are also grateful to the ICBP SurvMark-2 Academic Reference Group for providing independent peer review and advice for the study protocol and analysis plan development. Finally we are thankful to the ICBP Program Board for their oversight and direction. A complete list of all investigators can be found in page 2 of the Supplementary Materials. Publisher Copyright: {\textcopyright} 2020 World Health Organization",

year = "2020",

month = apr,

doi = "10.1016/j.ygyno.2019.12.047",

language = "English",

volume = "157",

pages = "234--244",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Elsevier",

number = "1",

}

Cabasag, CJ, Butler, J, Arnold, M, Rutherford, M, Bardot, A, Ferlay, J, Morgan, E, Møller, B, Gavin, A, Norell, CH, Harrison, S, Saint-Jacques, N, Eden, M, Rous, B, Nordin, A, Hanna, L, Kwon, J, Cohen, PA, Altman, AD, Shack, L, Kozie, S, Engholm, G, De, P, Sykes, P, Porter, G, Ferguson, S, Walsh, P, Trevithick, R, Tervonen, H, O'Connell, D, Bray, F & Soerjomataram, I 2020, 'Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study', Gynecologic Oncology, vol. 157, no. 1, pp. 234-244. https://doi.org/10.1016/j.ygyno.2019.12.047

TY - JOUR

T1 - Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2)

T2 - A population-based study

AU - Cabasag, Citadel J.

AU - Butler, John

AU - Arnold, Melina

AU - Rutherford, Mark

AU - Bardot, Aude

AU - Ferlay, Jacques

AU - Morgan, Eileen

AU - Møller, Bjørn

AU - Gavin, Anna

AU - Norell, Charles H.

AU - Harrison, Samantha

AU - Saint-Jacques, Nathalie

AU - Eden, Michael

AU - Rous, Brian

AU - Nordin, Andy

AU - Hanna, Louise

AU - Kwon, Janice

AU - Cohen, Paul A.

AU - Altman, Alon D.

AU - Shack, Lorraine

AU - Kozie, Serena

AU - Engholm, Gerda

AU - De, Prithwish

AU - Sykes, Peter

AU - Porter, Geoff

AU - Ferguson, Sarah

AU - Walsh, Paul

AU - Trevithick, Richard

AU - Tervonen, Hanna

AU - O'Connell, Dianne

AU - Bray, Freddie

AU - Soerjomataram, Isabelle

N1 - Funding Information: The ICBP is funded by the Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; NHS England; Norwegian Cancer Society; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry; DG Health and Social Care, Scottish Government; Western Australia Department of Health; Public Health Wales NHS Trust. The authors would also like to thank the ICBP management team of Cancer Research UK for managing the program, the ICBP SurvMark-2 Local Leads for advice to understand the data, for their contributions to the study protocol and interpretation of the results and the ICBP Clinical Committees for their advice. We are also grateful to the ICBP SurvMark-2 Academic Reference Group for providing independent peer review and advice for the study protocol and analysis plan development. Finally we are thankful to the ICBP Program Board for their oversight and direction. A complete list of all investigators can be found in page 2 of the Supplementary Materials. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. Funding Information: The ICBP is funded by the Canadian Partnership Against Cancer ; Cancer Council Victoria ; Cancer Institute New South Wales ; Cancer Research UK ; Danish Cancer Society ; National Cancer Registry Ireland ; The Cancer Society of New Zealand ; NHS England ; Norwegian Cancer Society ; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry ; DG Health and Social Care, Scottish Government ; Western Australia Department of Health ; Public Health Wales NHS Trust . The authors would also like to thank the ICBP management team of Cancer Research UK for managing the program, the ICBP SurvMark-2 Local Leads for advice to understand the data, for their contributions to the study protocol and interpretation of the results and the ICBP Clinical Committees for their advice. We are also grateful to the ICBP SurvMark-2 Academic Reference Group for providing independent peer review and advice for the study protocol and analysis plan development. Finally we are thankful to the ICBP Program Board for their oversight and direction. A complete list of all investigators can be found in page 2 of the Supplementary Materials. Publisher Copyright: © 2020 World Health Organization

PY - 2020/4

Y1 - 2020/4

N2 - Objective: The study aims to evaluate the differences in ovarian cancer survival by age and stage at diagnosis within and across seven high-income countries. Methods: We analyzed data from 58,161 women diagnosed with ovarian cancer during 2010–2014, followed until 31 December 2015, from 21 population-based cancer registries in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Comparisons of 1-year and 3-year age- and stage-specific net survival (NS) between countries were performed using the period analysis approach. Results: Minor variation in the stage distribution was observed between countries, with most women being diagnosed with ‘distant’ stage (ranging between 64% in Canada and 71% in Norway). The 3-year all-ages NS ranged from 45 to 57% with Australia (56%) and Norway (57%) demonstrating the highest survival. The proportion of women with ‘distant’ stage was highest for those aged 65–74 and 75–99 years and varied markedly between countries (range:72–80% and 77–87%, respectively). The oldest age group had the lowest 3-year age-specific survival (20–34%), and women aged 65–74 exhibited the widest variation across countries (3-year NS range: 40–60%). Differences in survival between countries were particularly stark for the oldest age group with ‘distant’ stage (3-year NS range: 12% in Ireland to 24% in Norway). Conclusions: International variations in ovarian cancer survival by stage exist with the largest differences observed in the oldest age group with advanced disease. This finding endorses further research investigating international differences in access to and quality of treatment, and prevalence of comorbid conditions particularly in older women with advanced disease.

AB - Objective: The study aims to evaluate the differences in ovarian cancer survival by age and stage at diagnosis within and across seven high-income countries. Methods: We analyzed data from 58,161 women diagnosed with ovarian cancer during 2010–2014, followed until 31 December 2015, from 21 population-based cancer registries in Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. Comparisons of 1-year and 3-year age- and stage-specific net survival (NS) between countries were performed using the period analysis approach. Results: Minor variation in the stage distribution was observed between countries, with most women being diagnosed with ‘distant’ stage (ranging between 64% in Canada and 71% in Norway). The 3-year all-ages NS ranged from 45 to 57% with Australia (56%) and Norway (57%) demonstrating the highest survival. The proportion of women with ‘distant’ stage was highest for those aged 65–74 and 75–99 years and varied markedly between countries (range:72–80% and 77–87%, respectively). The oldest age group had the lowest 3-year age-specific survival (20–34%), and women aged 65–74 exhibited the widest variation across countries (3-year NS range: 40–60%). Differences in survival between countries were particularly stark for the oldest age group with ‘distant’ stage (3-year NS range: 12% in Ireland to 24% in Norway). Conclusions: International variations in ovarian cancer survival by stage exist with the largest differences observed in the oldest age group with advanced disease. This finding endorses further research investigating international differences in access to and quality of treatment, and prevalence of comorbid conditions particularly in older women with advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=85078748032&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2019.12.047

DO - 10.1016/j.ygyno.2019.12.047

M3 - Article

C2 - 32005583

AN - SCOPUS:85078748032

SN - 0090-8258

VL - 157

SP - 234

EP - 244

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 1

ER -

Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this